Greater China News
Rejuvenate Bio shows epigenetic reprogramming extends lifespan in normal mice
Longevity biotech Rejuvenate Bio has made new progress towards showing that gene therapy-mediated partial reprogramming can potentially combat age-related diseases and extend lifespan.
派格生物转战港交所，投后估值40亿元
2024年2月23日，港交所官网显示，派格生物医药（苏州）股份有限公司（以下简称：“派格生物”）递交港交所上市申请，中金公司为独家保荐人。(点击下载：派格生物招股说明书)
ORI Capital Raises $260 Million for Second Life Sciences Fund
ORI Capital today announced the final close of its second fund, ORI Fund II (the “Fund”), with total commitments of $260 million
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on February 22, 2024 in Hong Kong.
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
I-Mab (the "Company") (NASDAQ: IMAB), a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment to patients around the world, today announced that as part of its strategy to become a U.S.-based biotech, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma (Hangzhou) Co., Ltd. (the "Hangzhou Company"), an unconsolidated affiliate of the Company, and a group of China-based investors to divest the Company's assets and business operations in China.
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance
YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company received a requisition to convene an extraordinary general meeting ("EGM") of the Company (the "Requisition") from APEX Prospect Limited (the "Requisitioning Shareholder"), a registered member of the Company that holds no less than 10% of the aggregate voting power of the Company's share capital as of February 12, 2024.
/C O R R E C T I O N — YS Biopharma Co., Ltd./
YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on February 16, 2024 in Seattle, United States.
YS Biopharma Announces Appointment of New Directors
In addition to the new appointments, the Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board
LianBio Announces Completion of Strategic Review
The Company currently anticipates a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024.
Brii Biosciences Announces Agreement to Acquire VBI’s IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Under these agreements, Brii Bio will issue a $2.5 million promissory note to VBI initially.
